Fertility preservation and pregnancy in women with and without BRCA mutation-positive breast cancer

Oncologist

Volumn 17, Issue 11, 2012, Pages 1409-1417

  Rodriguez Wallberg, Kenny A ^a   Oktay, Kutluk ^a  

^a NEW YORK MEDICAL COLLEGE   (United States)

Author keywords

BRCA mutations; Breast cancer; Chemotherapy; Estrogen receptor positive cancer; Female; Fertility preservation

Indexed keywords

BRCA1 PROTEIN; BRCA2 PROTEIN; CHORIONIC GONADOTROPIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; ESTROGEN; FOLLITROPIN; GONADORELIN; GONADORELIN ANTAGONIST; HORMONE RECEPTOR; LETROZOLE; LUTEINIZING HORMONE; MUELLERIAN INHIBITING FACTOR; TAMOXIFEN;

AMENORRHEA; ARTICLE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER SURVIVOR; CRYOPRESERVATION; DNA REPAIR; FEMALE FERTILITY; FERTILIZATION IN VITRO; GENE MUTATION; HUMAN; MENSTRUAL CYCLE; NONHUMAN; OOCYTE RETRIEVAL; OVARIAN RESERVE; PATIENT REFERRAL; PREGNANCY; PREGNANCY TEST; PRENATAL DIAGNOSIS; PRIORITY JOURNAL; REPRODUCTIVE PROCEDURE; SALPINGOOOPHORECTOMY; TISSUE TRANSPLANTATION;

ANTINEOPLASTIC AGENTS; AROMATASE INHIBITORS; BREAST NEOPLASMS; CRYOPRESERVATION; FEMALE; FERTILITY PRESERVATION; GENES, BRCA1; GENES, BRCA2; HUMANS; INFERTILITY, FEMALE; OOCYTE RETRIEVAL; OVULATION INDUCTION; PREGNANCY; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE;

EID: 84869386847     PISSN: 10837159     EISSN: 1549490X     Source Type: Journal    
DOI: 10.1634/theoncologist.2012-0236     Document Type: Article

References (58)

1. Blakely LJ, Buzdar AU, Lozada JA et al. Effects of pregnancy after treatment for breast carcinoma on survival and risk of recurrence. Cancer 2004;100:465-469.
2. Ives A, Saunders C, Bulsara M et al. Pregnancy after breast cancer: Population based study. BMJ 2007;334: 194.
3. Largillier R, Savignoni A, Gligorov J et al. Prognostic role of pregnancy occurring before or after treatment of early breast cancer patients aged < 35 years: A GET(N)A Working Group analysis. Cancer 2009;115: 5155-5165.
4. Sankila R, Heinavaara S, Hakulinen T. Survival of breast cancer patients after subsequent term pregnancy: "Healthy mother effect." Am J Obstet Gynecol 1994; 170:818-823.
5. Pagani O, Partridge A, Korde L et al.; Breast International Group; North American Breast Cancer Group Endocrine Working Group. Pregnancy after breast cancer: If you wish, ma'am. Breast Cancer Res Treat 2011; 129:309-317.
6. Rajkumar L, Guzman RC, Yang J et al. Short-term exposure to pregnancy levels of estrogen prevents mammary carcinogenesis. Proc Natl Acad Sci U S A 2001; 98:11755-11759.
7. Tsukamoto R, Mikami T, Miki K et al. N-methyl-Nnitrosourea- induced mammary carcinogenesis is promoted by short-term treatment with estrogen and progesterone mimicking pregnancy in aged female Lewis rats. Oncol Rep 2007;18:337-342.
8. Breast cancer and breastfeeding: Collaborative reanalysis of individual data from 47 epidemiological studies in 30 countries, including 50302 women with breast cancer and 96973 women without the disease. Lancet 2002;360:187-195.
9. Andrieu N, Goldgar DE, Easton DF et al. Pregnancies, breast-feeding, and breast cancer risk in the International BRCA1/2 Carrier Cohort Study (IBCCS). J Natl Cancer Inst 2006;98:535-544.
10. Antoniou AC, Shenton A, Maher ER et al. Parity and breast cancer risk among BRCA1 and BRCA2 mutation carriers. Breast Cancer Res 2006;8:R72.
11. Cullinane CA, Lubinski J, Neuhausen SL et al. Effect of pregnancy as a risk factor for breast cancer in BRCA1/BRCA2 mutation carriers. Int J Cancer 2005; 117:988-991.
12. Jernström H, Lerman C, Ghadirian P et al. Pregnancy and risk of early breast cancer in carriers of BRCA1 and BRCA2. Lancet 1999;354:1846-1850.
13. Milne RL, Osorio A, Ramón y Cajal T et al. Parity and the risk of breast and ovarian cancer in BRCA1 and BRCA2 mutation carriers. Breast Cancer Res Treat 2010; 119:221-232.
14. Kotsopoulos J, Librach CL, Lubinski J et al. Infertility, treatment of infertility, and the risk of breast cancer among women with BRCA1 and BRCA2 mutations: A case-control study. Cancer Causes Control 2008;19: 1111-1119.
15. Sonmezer M, Oktay K. Fertility preservation in young women undergoing breast cancer therapy. The Oncologist 2006;11:422-434.
16. Oktay K, Kim JY, Barad D et al. Association of BRCA1 mutations with occult primary ovarian insufficiency: A possible explanation for the link between infertility and breast/ovarian cancer risks. J Clin Oncol 2010;28:240-244.
17. Rzepka-Górska I, Tarnowski B, Chudecka-Glaz A et al. Premature menopause in patients with BRCA1 gene mutation. Breast Cancer Res Treat 2006;100:59-63.
18. Faddy MJ, Gosden RG, Gougeon A et al. Accelerated disappearance of ovarian follicles in mid-life: Implications for forecasting menopause. Hum Reprod 1992;7:1342-1346.
19. Toner JP, Flood JT. Fertility after the age of 40. Obstet Gynecol Clin North Am 1993;20:261-272.
20. Oktem O, Oktay K. Quantitative assessment of the impact of chemotherapy on ovarian follicle reserve and stromal function. Cancer 2007;110:2222-2229.
21. La Marca A, Sighinolfi G, Radi D et al. Anti-Mullerian hormone (AMH) as a predictive marker in assisted reproductive technology (ART). Hum Reprod Update 2010;16:113-130.
22. Rosen MP, Johnstone E, McCulloch CE et al. A characterization of the relationship of ovarian reserve markers with age. Fertil Steril 2012;97:238-243.
23. Gracia CR, Sammel MD, Freeman E et al. Impact of cancer therapies on ovarian reserve. Fertil Steril 2012; 97:134-140.e1.
24. Rosen A, Rodriguez-Wallberg KA, Rosenzweig L. Psychosocial distress in young cancer survivors. Semin Oncol Nurs 2009;25:268-277.
25. Rosen AB, Oktay K. Fertility preservation provides hope to cancer patients. Fertil Steril 2011;96(3 suppl):O-30.
26. Oktay K, Cil AP, Bang H. Efficiency of oocyte cryopreservation: A meta-analysis. Fertil Steril 2006;86: 70-80.
27. Practice Committee of the American Society for Reproductive Medicine; Practice Committee of the Society for Assisted Reproductive Technologies. Ovarian tissue and oocyte cryopreservation. Fertil Steril 2008; 90(5 suppl):S241-S246.
28. Practice Committee of the American Society for Reproductive Medicine. ASRM Practice Committee response to Rybak and Lieman: Elective self-donation of oocytes. Fertil Steril 2009;92:1513-1514.
29. Oktay K, Buyuk E, Davis O et al. Fertility preservation in breast cancer patients: IVF and embryo cryopreservation after ovarian stimulation with tamoxifen. Hum Reprod 2003;18:90-95.
30. Shalom-Paz E, Almog B, Shehata F et al. Fertility preservation for breast-cancer patients using IVM followed by oocyte or embryo vitrification. Reprod Biomed Online 2010;21:566-571.
31. Oktay K, Demirtas E, Son WY et al. In vitro maturation of germinal vesicle oocytes recovered after premature luteinizing hormone surge: Description of a novel approach to fertility preservation. Fertil Steril 2008;89:228.e19-e22.
32. Sönmezer M, Türkc ̧üog ̌lu I, Coskun U et al. Random- start controlled ovarian hyperstimulation for emergency fertility preservation in letrozole cycles. Fertil Steril 2011;95:2125.e9-e11.
33. Baerwald AR, Adams GP, Pierson RA. Characterization of ovarian follicular wave dynamics in women. Biol Reprod 2003;69:1023-1031.
34. Kauff ND, Satagopan JM, Robson ME et al. Riskreducing salpingo-oophorectomy in women with a BRCA1 or BRCA2 mutation. N Engl J Med 2002;346: 1609-1615.
35. Haldar K, Giamougiannis P, Wilson C et al. Laparoscopic salpingo-oophorectomy for ovarian ablation in women with hormone-sensitive breast cancer. Int J Gynaecol Obstet 2011;113:222;224.
36. Oktay K, Karlikaya G. Ovarian function after transplantation of frozen, banked autologous ovarian tissue. N Engl J Med 2000;342:1919.
37. von Wolff M, Donnez J, Hovatta O et al. Cryopreservation and autotransplantation of human ovarian tissue prior to cytotoxic therapy-a technique in its infancy but already successful in fertility preservation. Eur J Cancer 2009;45:1547-1553.
38. Noyes N, Porcu E, Borini A. Over 900 oocyte cryopreservation babies born with no apparent increase in congenital anomalies. Reprod Biomed Online 2009;18: 769-776.
39. Lee S, Ozkavukcu S, Heytens E et al. Value of early referral to fertility preservation in young women with breast cancer. J Clin Oncol 2010;28:4683-4686.
40. Richards L. Fertility: The importance of early referral to fertility preservation. Nat Rev Clin Oncol 2011; 8:4.
41. Casper RF, Mitwally MF. Review: Aromatase inhibitors for ovulation induction. J Clin Endocrinol Metab 2006;91:760-771.
42. Oktay K, Buyuk E, Libertella N et al. Fertility preservation in breast cancer patients: A prospective controlled comparison of ovarian stimulation with tamoxifen and letrozole for embryo cryopreservation. J Clin Oncol 2005;23:4347-4353.
43. Oktay K, Hourvitz A, Sahin G et al. Letrozole reduces estrogen and gonadotropin exposure in women with breast cancer undergoing ovarian stimulation before chemotherapy. J Clin Endocrinol Metab 2006;91: 3885-3890.
44. Azim AA, Costantini-Ferrando M, Lostritto K et al. Relative potencies of anastrozole and letrozole to suppress estradiol in breast cancer patients undergoing ovarian stimulation before in vitro fertilization. J Clin Endocrinol Metab 2007;92:2197-2200.
45. Azim AA, Costantini-Ferrando M, Oktay K. Safety of fertility preservation by ovarian stimulation with letrozole and gonadotropins in patients with breast cancer: A prospective controlled study. J Clin Oncol 2008; 26:2630-2635.
46. Oktay K, Lee S, Kim JY et al. Long-term outcomes and safety of letrozole-FSH protocol in women with breast cancer undergoing fertility preservation: A prospective- controlled study. Fertil Steril 2010;94(4 suppl): S11.
47. Oktay K, Turkcuoglu I, Rodriguez-Wallberg KA. GnRH agonist trigger for women with breast cancer undergoing fertility preservation by aromatase inhibitor/ FSH stimulation. Reprod Biomed Online 2010;20:783-788.
48. Lin WT, Beattie M, Chen L-M et al. Age of natural menopause in BRCA 1/2 mutation carriers. Fertil Steril 2010;94(4 suppl):S43.
49. Pal T, Keefe D, Sun P et al. Fertility in women with BRCA mutations: A case-control study. Fertil Steril 2010;93:1805-1808.
50. Oktay K, Economos K, Kan M et al. Endocrine function and oocyte retrieval after autologous transplantation of ovarian cortical strips to the forearm. JAMA 2001;286:1490-1493.
51. Oktay K, Buyuk E, Veeck L et al. Embryo development after heterotopic transplantation of cryopreserved ovarian tissue. Lancet 2004;363:837-840.
52. Albain KS, Barlow WE, Ravdin PM et al.; Breast Cancer Intergroup of North America. Adjuvant chemotherapy and timing of tamoxifen in postmenopausal patients with endocrine-responsive, node-positive breast cancer: A phase 3, open-label, randomised controlled trial. Lancet 2009;374:2055-2063.
53. Saloustros E, Stratakis CA. Potential late effect of gonadotropin-releasing hormone agonists in combination with chemotherapy for early breast cancer. J Clin Oncol 2012;30:3311-3312.
54. Sagi M, Weinberg N, Eilat A et al. Preimplantation genetic diagnosis for BRCA1/2-a novel clinical experience. Prenat Diagn 2009;29:508-513.
55. Quinn GP, Vadaparampil ST, Bower B et al. Decisions and ethical issues among BRCA carriers and the use of preimplantation genetic diagnosis. Minerva Med 2009;100:371-383.
56. Fortuny D, Balmaña J, Graña B et al. Opinion about reproductive decision making among individuals undergoing BRCA1/2 genetic testing in a multicentre Spanish cohort. Hum Reprod 2009;24:1000-1006.
57. Ormondroyd E, Donnelly L, Moynihan C et al. Attitudes to reproductive genetic testing in women who had a positive BRCA test before having children: A qualitative analysis. Eur J Hum Genet 2012;20:4-10.
58. Armuand G, Rodriguez Wallberg KA, Wettergren L et al. Sex differences in fertility-related information received by young adult cancer survivors. J Clin Oncol 2012;30:2147-2153.